Panacea Biotec surges 10% on collaboration with Serum Institute of India

The stock surges 10% to Rs 284 after the company signed two long term agreements with Serum Institute of India and its wholly owned subsidiary, Bilthovan Biologicals BV

Panacea Biotec surged 10% to Rs 284 on BSE in intra-day trade after the company announced the collaboration with signing of two long term agreements with Serum Institute of India(SII) and SII's wholly owned subsidiary, Bilthovan Biologicals BV (BBIO).

Under the collaboration, SII is entitled to manufacture & sell fully liquid Whole cell Pertussis (wP) and Salk based Injectable Polio Vaccine (IPV) based Hexavalent vaccine (DTwP-HepB-Hib-IPV) developed & commercialized by Panacea Biotec, a first of its kind in this category.

“Serum Institute of India will ensure supply of IPV bulk to Panacea Biotec, an important constituent of the